Algoma District Cancer Program Sault Area Hospital

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Ovarian cancer2 trials
• Endometrial cancer1 trial
• Lung cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial
• Sarcoma1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 38 trials
• Phase 2/31 trial

Status

• Active, not recruiting7 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• National Cancer Institute (NCI)8 trials
• University of Sydney1 trial

Running trials

• Active, not recruiting

  Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

  NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02446600· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

  NCT02446405· Phase 3· University of Sydney· Source

Closed trials

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source